Related Experiment Video
Updated: May 21, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
Published on: June 4, 2012
Successful combination therapy with vancomycin and arbekacin against infective endocarditis caused by MRSA
Kentaro To1, Noriko Miyake, Yoji Nagasaki
1Department of Clinical Immunology and Rheumatology/Infectious Diseases, Kyushu University Hospital.
Abstract:
Infective endocarditis caused by methicillin-resistant Staphylococcus aureus (MRSA) is a serious disease and sometimes leads to poor prognosis. We should have several therapeutic options. Arbekacin is one of the aminoglycoside antibiotics, which is more active against MRSA and less nephrotoxic than gentamicin. Here we presented a successfully treated case of severe MRSA endocarditis without any adverse effect by monitoring therapeutic level of vancomycin and arbekacin.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Endocarditis III: Medical Management
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Mechanism of Antibiotic Resistance in MRSA
Endocarditis IV: Nursing Management
Antimicrobial Effectiveness
